{"id":55351,"date":"2025-04-17T11:00:00","date_gmt":"2025-04-17T05:30:00","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=55351"},"modified":"2025-04-17T12:02:19","modified_gmt":"2025-04-17T06:32:19","slug":"trumps-new-health-order-the-unexpected-boost-for-indian-pharma","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/trumps-new-health-order-the-unexpected-boost-for-indian-pharma\/","title":{"rendered":"Trump\u2019s New Health Order: The Unexpected Boost for Indian Pharma\u00a0"},"content":{"rendered":"
<\/div>\n

What Does the Executive Order Include?<\/strong><\/h2>\n\n\n\n

Trump\u2019s executive order comprises several core reforms:<\/p>\n\n\n\n

    \n
  1. International Reference Pricing<\/strong>: Drug prices under Medicare will be benchmarked against those in Canada, Germany, and Australia.
    <\/li>\n\n\n\n
  2. Import Expansion<\/strong>: The FDA will expedite pathways for importing low-cost generics and biosimilars.
    <\/li>\n\n\n\n
  3. Hospital Procurement Reforms<\/strong>: Hospitals under federal programs must prioritize cost-effective suppliers.
    <\/li>\n\n\n\n
  4. Patent Review and Reuse Policy<\/strong>: The administration will incentivize generic manufacturing and challenge anti-competitive patent extensions.
    <\/li>\n<\/ol>\n\n\n\n

    These changes, aimed at breaking monopolistic pricing, also signal that the U.S. is ready to embrace cheaper imports to protect domestic affordability.  Source<\/strong>: New York Times, April 15, 2025<\/a><\/p>\n\n\n\n

    India\u2019s Competitive Advantage in a New Global<\/a> Pharma Order<\/strong><\/p>\n\n\n\n

    India, known as the “pharmacy of the world,” already accounts for 20% of global generics exports by volume<\/strong>, according to Statista<\/strong>. The U.S. is its largest market, accounting for nearly 32% of India\u2019s pharma exports<\/strong> in FY2024. <\/p>\n\n\n\n

    \"\"
    Source: Reuters<\/a><\/figcaption><\/figure>\n\n\n\n

    <\/p>\n\n\n\n

    \"\"
    Source: Statista<\/a><\/figcaption><\/figure>\n\n\n\n

    <\/p>\n\n\n\n

    Here are two key insights to know about<\/h2>\n\n\n\n
      \n
    1. India vs China \u2013 FDA-Approved Facilities:<\/strong> India leads with over 750 U.S. FDA-approved pharma plants, compared to China’s ~120.
      <\/li>\n\n\n\n
    2. India\u2019s Pharma Export Share:<\/strong> The U.S. is India\u2019s top destination for pharma exports, accounting for 32% of total shipments in FY2024.<\/li>\n<\/ol>\n\n\n\n

      With the U.S. government actively looking to bring down prices, Indian manufacturers offering cost savings of 30\u201370%<\/strong> over Western peers are in a strong position. Companies like Sun Pharma, Dr. Reddy\u2019s Laboratories, Cipla, and Aurobindo<\/strong> are well-placed due to their robust regulatory compliance and existing U.S. FDA-approved manufacturing facilities.  <\/p>\n\n\n\n

      Metric<\/strong><\/td>Current (2024)<\/strong><\/td>Post-Order Estimate (2025-26)<\/strong><\/td><\/tr>
      India Pharma Exports to the U.S.<\/td>$8.2 billion<\/td>$10.5\u2013$12 billion<\/td><\/tr>
      U.S. Generic Drug Imports<\/td>$58 billion<\/td>$65\u2013$70 billion<\/td><\/tr>
      % of U.S. generics from India<\/td>40%<\/td>>50%<\/td><\/tr>
      U.S. Drug Cost Savings<\/td>\u2014<\/td>$30 billion (Est. by 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Sources<\/strong>: Reuters, Economic Times, U.S. Congressional Budget<\/a> Office Estimates<\/p>\n\n\n\n

      Winners and Losers<\/strong><\/h2>\n\n\n\n

      Winners:<\/strong><\/p>\n\n\n\n